Akums Drugs Q1 FY27 earnings: key numbers for 2026

Earnings date and what is scheduled

Akums Drugs & Pharmaceuticals is set to report earnings with a board meeting scheduled for August 08, 2026. The meeting agenda includes considering the audited financial results and a recommendation on dividend for FY2026. For investors, the key near-term focus is whether operating profitability sustains after a volatile run of quarterly operating profit in the standalone numbers. The company’s recent disclosures also put attention on the CDMO segment, which has been described as the largest revenue contributor.

Stock price action heading into the results

The stock has seen multiple reference points in recent market updates. On the NSE at 4:00 PM on 07 Aug, the share price was reported at ₹697.45, up ₹34.90 (5.27%). Another data point notes that as of 4 Aug 2026, the share price was ₹681.2. A separate “CMP” snapshot lists ₹666.1, indicating that prices have moved quickly over a short period. These levels matter mainly because they frame expectations into the results date and the dividend recommendation decision.

Previous quarter baseline: revenue, profit, and margin

A “Quick Details” snapshot lists the previous quarter revenue at ₹1,158 crore, previous quarter PAT at ₹81 crore, and previous quarter EBITDA margin at 13.1%. These are the immediate comparables many traders use when positioning into an earnings event. The EBITDA margin number is also relevant because other commentary in the provided material references margin bands around the low-to-mid teens for the business.

March 2026 sales: standalone versus consolidated

For the March 2026 quarter, two separate updates were provided for net sales. Standalone March 2026 net sales were ₹338.37 crore, up 2.93% YoY, while consolidated March 2026 net sales were ₹1,157.87 crore, up 9.69% YoY. The gap between standalone and consolidated values highlights how much of the business footprint sits outside the standalone entity. For readers comparing performance quarter-to-quarter, it is important to note that the standalone quarterly table provided runs through Mar 2026, while the consolidated quarterly snapshot in the content runs through Dec 2025.

Q1 performance snapshot: income, EBITDA, and margins

The article text includes a set of Q1 performance numbers described as “Q1 results”. Under that snapshot, total income stood at ₹1,051.00 crore, representing a 2.40% year-on-year increase. Reported EBITDA rose 19% year-on-year to ₹156.00 crore, and the EBITDA margin expanded by 208 basis points to 14.80%. Separately, a Hindi excerpt also references revenue ₹140 crore, EBITDA ₹151 crore, and PAT ₹76 crore, along with an EBITDA margin of 13.2% and a note that the CDMO segment had ₹875 crore as the largest share of revenue. Since those figures appear as a transcript-style snippet, readers should treat them as a separate stated data point rather than a reconciled income statement.

Segment mix: where revenues were reported

The same Q1 snapshot breaks down segment revenues. The CDMO segment generated ₹813.00 crore in Q1 and was reported to have grown 4% YoY. Domestic branded formulations revenue was ₹107.00 crore, up 3.40% YoY, while international branded formulations revenue was ₹35.00 crore, up 2.40% YoY. On the other hand, the API business revenue was ₹45.00 crore, down 35% YoY, and trade generics revenue was ₹23.00 crore, down 21% YoY. Together, these figures point to a business where CDMO is the core contributor, while other lines can swing based on portfolio choices and rationalisation.

What the standalone quarterly table says about costs and operating profit

Standalone quarterly data (figures in ₹ crore) shows net sales moving from ₹328.75 crore in Mar 2025 to ₹338.37 crore in Mar 2026. Over the same period, total expenditure increased from ₹311.03 crore to ₹326.59 crore. Operating profit in the standalone table fluctuated, including ₹44.11 crore in Jun 2025, but falling to ₹11.79 crore in Mar 2026. The table also shows “other income” remaining sizable, such as ₹32.05 crore in Mar 2025 and ₹27.73 crore in Mar 2026, which can materially influence profit metrics beyond core operations.

Shareholding and market value reference points

Shareholding as of Jun ’26 was stated as promoters at 75.3%, FIIs 1.9%, DIIs 13.5%, and public 6.7%. Another holding table also repeatedly lists promoters at 75.26% across multiple quarters. On valuation, one update states market capitalisation of ₹10,977.44 crore based on the share price of ₹697.45. Another snapshot says that as of Jun ’26, market capitalisation stood at ₹10,721.68 crore. These figures serve as context for how the market is pricing the business into an earnings event and a dividend consideration.

Guidance and near-term operational cues

The text notes that the CDMO business expects double-digit volume growth in H1 FY27, with a broadly similar margin profile to current levels, described as around 13-14%. It also mentions potential margin improvement to 15-16% linked to new contracts in Europe and Zambia. This is not stated as a formal revenue growth guidance, but it is an operational cue investors often track for contract manufacturing businesses where capacity mix and customer geography can shift profitability.

Key data points to track on August 08

The earnings day focus will likely centre on how the audited numbers align with the previously stated revenue, PAT, and margin baselines, and whether the board recommends a dividend for FY2026 as indicated. Investors will also track whether CDMO continues to dominate the revenue mix around the reported levels, and whether the profitability uplift seen in EBITDA growth and margin expansion persists. Given the multiple reported price points in early August, the market reaction may hinge on margin delivery and segment trajectory rather than only top-line growth.

Conclusion

Akums Drugs & Pharmaceuticals heads into August 08, 2026 with attention split between the audited results and the board’s decision on a FY2026 dividend recommendation. The most cited reference points in the available information include a previous-quarter revenue of ₹1,158 crore, PAT of ₹81 crore, and EBITDA margin of 13.1%, along with Q1 snapshot figures showing EBITDA margin at 14.80%. Any formal announcements from the board meeting will clarify how these metrics are tracking and what shareholders can expect on dividends.